

Collection: EXTENSION, OMB control number 0925-0407, expiration date September 30, 1996. Need and Use of Information Collection Request: This trial is designed to determine if screening for prostate, lung, colorectal and ovarian cancer can reduce mortality from these cancers which currently cause an estimated 251,000 deaths annually in the U.S. The design is a two-armed randomized trial of men and women aged 55 to 74 at entry. The anticipated total sample size, after four and one half years of recruitment, is projected to be 148,000. The primary endpoint of the trial is cancer-specific mortality for each of the four cancer sites (prostate, lung, colorectal, and ovary). In addition, cancer incidence, stage shift, and case survival are to be monitored to help understand and explain results. Biologic prognostic characteristics of the cancers will be measured and correlated with mortality to determine the mortality predictive value of these intermediate endpoints. Basic demographic data, risk factor data for the four cancer sites and screening history data, as collected from all subjects at baseline, will be used to assure comparability between the screening and control groups and make appropriate adjustments in analysis. Further, demographic and risk factor information will be used to analyze the differential effectiveness of screening in high versus low risk individuals. Frequency of Response: On occasion. Affected Public: Individuals or households. Type of Respondents: Adult men and women. The annual reporting burden is as follows: Estimated Number of Respondents: 100,522; Estimated Number of Responses per Respondent: 1.98; Average Burden Hours Per Response: 0.59; and Estimated Total Annual Burden Hours Requested: 114,537. The annualized cost to respondents is estimated at: \$1,145,367. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

**REQUEST FOR COMMENTS:** Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and

clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**DIRECT COMMENTS TO OMB:** Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, D.C. 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. John Gohagan, Chief, Early Detection Branch, EDCOP, National Cancer Institute, NIH, EPN Building, Room 330, 6130 Executive Boulevard, MSC7346, Bethesda, MD 20892-7346, or call non-toll-free number (301) 496-3982 or E-mail your request, including your address to:

gohaganj@dcpcepn.nih.gov  
**COMMENTS DUE DATE:** Comments regarding this information collection are best assured of having their full effect if received on or before September 19, 1996.

Dated: August 9, 1996.  
Philip D. Amoroso,  
*Executive Officer, NCI.*  
[FR Doc. 96-21127 Filed 8-19-96; 8:45 am]  
**BILLING CODE 4140-01-M**

### **National Eye Institute; Notice of Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Eye Institute Special Emphasis Panel (SEP) meeting:

*Name of SEP:* Clinical Research.  
*Date:* August 23, 1996.  
*Time:* 9:00 a.m.  
*Place:* National Eye Institute, Executive Plaza South, Suite 350, 6120 Executive Blvd., Bethesda, MD 20892-7164.

*Contact Person:* Andrew P. Mariani, Ph.D., Executive Plaza South, Room 350, 6120 Executive Blvd., Bethesda, MD 20892-7164, (301) 496-5561.

*Purpose/Agenda:* Review of Grant Applications.

The meeting will be closed in accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or

commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program No. 93.867, Vision Research: National Institutes of Health)

Dated: August 13, 1996.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 96-21133 Filed 8-19-96; 8:45 am]

**BILLING CODE 4140-01-M**

### **National Institute of Environmental Health Sciences; Notice of Meeting of Board of Scientific Counselors, National Institute of Environmental Health Sciences**

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Board of Scientific Counselors, National Institute of Environmental Health Sciences, September 29-October 1, 1996, in Building 101, South Campus, Conference Rooms A, B, & C, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, North Carolina.

This meeting will be open to the public from 8:30 a.m. on September 30 to approximately 10:30 a.m. on October 1, for the purpose of presenting an overview of the organization and conduct of research in the Laboratory of Molecular Carcinogenesis, the Laboratory of Experimental Pathology, and the Cancer Genetics Section (LECM). Attendance by the public will be limited to space available.

In accordance with the provisions set forth in sec. 552b(c)(6) of Title 5, U.S. Code and sec. 10(d) of Public Law 92-463, the meeting will be closed to the public on September 29 from approximately 8:00 p.m. to 9:30 p.m. and on October 1, from 10:30 a.m. to adjournment, for the evaluation of the programs of the laboratories listed above, including consideration of personnel qualifications and performance, the competence of individual investigators, and similar items, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

The Executive Secretary, Dr. Carl Barrett, Scientific Director, Division of Intramural Research, NIEHS, Research Triangle Park, NC 27709, telephone (919) 541-3205, will furnish rosters of committee members and program information.